INKJET REFILLING ADAPTER

Embodiments provide an inkjet cartridge refilling system. The system may include a drill station configured to drill at least one refilling hole in an inkjet printer cartridge. The system may include an evacuation station configured to remove excess ink from the inkjet printer cartridge. In some embodiments, the excess ink is removed via a vacuum source. The system may also include a filling station configured to provide any of a plurality of inks into the cartridge. Some embodiments provide the ink to the inkjet cartridge via a hole drilled in the cartridge. Other embodiments provide the ink via inkjet nozzles of the inkjet printer cartridge. The system may also include a test station configured to test the refilled cartridge to determine whether it is functioning properly after being filled with ink. 1. An adapter configured to mate with an inkjet printer cartridge , wherein the inkjet printer cartridge has an electrical interface , said adapter comprising:at least one support surface; anda second surface connected to the support surface and having a first face and a second face, wherein the first face comprises electrical contacts configured to mate with the electrical interface on the inkjet printer cartridge, and wherein the second face comprises electrical contacts configured to mate with a receiver on an inkjet refilling system.2. The adapter of claim 1 , wherein the at least one support surface is a pair of vertical support surfaces.3. The adapter of claim 2 , wherein the pair of vertical supports are connected by the second surface.4. The adapter of claim 1 , wherein the second face is configured to mate with an electrical connection at the receiving of the inkjet refilling system.5. The adapter of claim 1 , wherein the adapter further comprises a unique identifier that can be read by an inkjet refilling system.6. The adapter of claim 5 , wherein the unique identifier comprises at least one magnet claim 5 , a bar code or an RFID tag.7. The adapter of claim ...

GARMENT WITH INTEGRATED FALL ARREST SAFETY HARNESS

In some examples, a kit comprising a garment to be worn by a user; a fall arrest safety harness integrated into the garment; and a suspension relief strap configured to be coupled to the fall arrest safety harness, and wherein the fall arrest safety harness is integrated into the garment such that, when the garment is worn by the user, the fall arrest safety harness is worn by the user in a manner that arrests a fall by the user when the fall arrest safety harness is anchored. 1. A kit comprising:a garment to be worn by a user;a fall arrest safety harness integrated into the garment; anda suspension relief strap configured to be coupled to the fall arrest safety harness, and wherein the fall arrest safety harness is integrated into the garment such that, when the garment is worn by the user, the fall arrest safety harness is worn by the user in a manner that arrests a fall by the user when the fall arrest safety harness is anchored.2. The kit assembly of claim 1 , wherein the safety harness is removable from the garment.3. The kit assembly of claim 1 , wherein the safety harness includes a coupling by which to couple to at least one of a removable tether claim 1 , an anchor strap and a tree strap.4. The kit assembly of claim 1 , further comprising the at least one of the removable tether claim 1 , the anchor strap and the tree strap.5. The kit assembly of claim 1 , wherein the safety harness is not overtly visible when viewing the garment.6. The kit assembly of claim 1 , wherein the garment comprises overalls.7. The kit assembly of claim 1 , wherein the garment includes a portion that claim 1 , when worn by the user claim 1 , substantially surrounds an upper thigh area of the user.8. The kit assembly of claim 1 , wherein the garment comprises an odor-control garment.9. The kit assembly of claim 1 , further comprising a tether configured to anchor the fall arrest safety harness.10. The kit assembly of claim 9 , wherein the tether is coupled to the fall arrest safety ...

COMPOSITE FABRIC WITH ADSORBENT POLYMER MATERIAL

In some aspects, the disclosure relates to composite fabric assembly comprising a fabric substrate including a surface and a layer adhered to or impregnated into the surface of the fabric substrate, the layer including polymer resin particles, wherein polymer resin particles are configured to adsorb at least one of an organic compound, inorganic compound, or chemicals. 1. A composite fabric assembly comprising:a fabric substrate including a surface; anda layer adhered to or impregnated into the surface of the fabric substrate, the layer including polymer resin particles, wherein the polymer resin particles are configured to adsorb at least one of an organic compound, inorganic compound, or chemicals.2. The assembly of claim 1 , wherein the layer including polymer resin particles comprises a substantially continuous layer over the surface of the fabric substrate.3. The assembly of claim 1 , wherein the layer including polymer resin particles comprises a discontinuous layer over the surface of the fabric substrate.4. The assembly of claim 3 , wherein the discontinuous layer over the surface of the fabric substrate is defined by a plurality of discrete deposits of the polymer resin particles separated by gaps on the surface of the fabric substrate claim 3 , and wherein the plurality of discrete deposits of the polymer resin particles separated by gaps on the surface of the fabric substrate are arranged according to a predetermined pattern.5. The assembly of claim 1 , wherein the polymer resin particles exhibit a particle size less than approximately 200 microns.6. The assembly of claim 5 , wherein the polymer resin particles exhibit a particle size less than approximately 100 microns.7. The assembly of claim 1 , wherein the polymer resin particles adsorb body odor.8. The assembly of claim 7 , wherein the polymer resin particles adsorb short chain carboxylic fatty acids.9. The assembly of claim 8 , wherein the short chain carboxylic fatty acids include at least one of ...

AUTOMATED SMART STORAGE OF PRODUCTS

Automated, environmentally monitored and controlled storage units and systems for storing, monitoring, and maintaining a supply of products, particularly temperature sensitive pharmaceutical and/or other high-value products, be they temperature sensitive or not. Such automated storage units contain an array of independently addressable holding locations for containers with product in one or more environmentally monitored (e.g., for temperature, humidity, etc.) and controlled zones fitted with appropriate environmental sensors. In preferred embodiments, the automated storage units also include a reader to track product information and status. Product loading, retrieval, and movement within such automated storage units is performed by a computer-controlled robot. A user interface device, preferably in communication with an application service provider to provide remotely managed inventory management and other services, provides users with inventory- and product-specific information. 1. An automated product storage unit , comprising:(i) a housing comprising at least one product access panel to facilitate loading and/or retrieving products stored therein;(ii) disposed in the housing, at least one storage area framework comprising a plurality of independently addressable storage bays configured to store one or more product containers and/or empty and/or loaded product carriers;(iii) disposed in the housing, at least one accessible storage zone that bounds a first volume that encloses at least a portion of the plurality of independently addressable storage bays in the storage area framework(s), which storage zone optionally comprises at least one environmental parameter sensor, optionally a temperature sensor;(iv) disposed in the housing adjacent to the accessible storage zone, a loading zone accessible to a user via a product access panel and comprising a moveable loading tray that comprises plurality of sensed loading slots each configured to receive a product container ...

SOLID PRODRUG FORMS OF 2'-CHLORO-2'-METHYL URIDINE FOR HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are solid forms of Compound I: (Compound I) 2. Compound I of where the compound is in substantially pure crystalline form.3. Compound I of claim 1 , wherein said compound is Form I claim 1 , and said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 1 , about 15.7 claim 1 , and about 18.5.4. Compound I of claim 2 , wherein said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 2 , about 15.7 claim 2 , about 18.5 claim 2 , about claim 2 , 18.0 about 13.6 claim 2 , and about 10.8.5. Compound I of claim 3 , wherein said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 3 , about 15.7 claim 3 , about 18.5 claim 3 , about 10.8 claim 3 , about 13.6 claim 3 , about 18.0 claim 3 , about 7.3 claim 3 , about 8.2 claim 3 , and about 19.3.6. Compound I of claim 4 , wherein said Form I is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 6.8 claim 4 , about 15.7 claim 4 , about 18.5 claim 4 , about 10.8 claim 4 , about 13.6 claim 4 , about 18.0 claim 4 , about 7.3 claim 4 , about 8.2 claim 4 , about 19.3 claim 4 , about 16.8 claim 4 , about 19.7 claim 4 , about 21.4 claim 4 , about 21.8 claim 4 , about 23.6 claim 4 , about 24.4 claim 4 , about 24.8 and about 26.5.7. Compound I of wherein said compound is Form I claim 1 , and said From I is characterized by ...

CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR

The present invention relates to different forms of a HCV inhibitory compound. 1. Compound A having a form selected from the group consisting of:{'sub': 'α', 'a) Hydrate III, wherein Hydrate III is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 20.5, 5.0, and 18.2; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 5.14, 6.31, 12.49, 18.35, 26.81, 28.03, 30.33, 31.27, 34.95, 35.99, 38.68, 42.01, 54.93, 56.39, 60.14, 74.20, 107.02, 120.11, 121.60, 129.73, 134.35, 135.95, 142.89, 148.47, 155.37, 157.32, 160.90, 168.32, 172.17, and 175.53 ppm;'}{'sub': 'α', 'b) Hydrate II, wherein Hydrate II is characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 11.7, 16.6, and 11.2;'}{'sub': 'α', 'c) a crystalline Na salt characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 18.4, 9.1, and 9.8;'}{'sub': 'α', 'd) a crystalline K salt characterized by an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 18.2, 8.9, and 20.3;'}{'sub': 'α', 'e) Hydrate I, wherein Hydrate I is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 8.6, 20.6, and 26.6; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 4.22, 7.23, 11.45, 17.79, 24.04, 26.95, 28.29, 31.15, 32.47, 32.47, 33.46, 34.03, 35.74, 42.32, 53.50, 56.05, 56.96, 77.49, 108.95, 119.65, 122.55, 131.05, 133.13, 135.38, 142.28, 150.78, 156.03, 157.99, 161.36, 171.40, 173.42, 174.30 ppm;'}{'sub': 'α', 'f) Hydrate IV, wherein Hydrate IV is characterized by either (i) an X-ray powder diffraction pattern obtained using copper K radiation which comprises 2Θ values in degrees of about 14.7, 11.5, and 7.1; or (ii ...

CRYSTAL FORMS OF A M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR

The invention is directed to novel anhydrous crystalline butenedioate salt form 1 of Compound I, which is a modulator of muscarinic M1 receptors. The novel crystalline forms of compound I are useful in the treatment or prevention of Alzheimer's disease and other disorders and diseases in which muscarinic M1 receptors are involved. The invention is further directed to pharmaceutical compositions comprising the novel crystalline forms of Compound I. 21. The compound of characterized by an x-ray powder diffraction pattern claim 20 , collected using copper K-alpha radiation claim 20 , corresponding to d-spacings of 18.78 claim 20 , 12.81 claim 20 , 9.24 claim 20 , 8.97 claim 20 , 8.09 claim 20 , 6.84 claim 20 , 6.40 claim 20 , 5.83 claim 20 , 5.71 claim 20 , 5.45 claim 20 , 5.09 claim 20 , 5.04 claim 20 , 4.86 claim 20 , 4.73 claim 20 , 4.63 claim 20 , 4.58 claim 20 , 4.52 claim 20 , 4.38 claim 20 , 4.19 claim 20 , 4.17 claim 20 , 4.06 claim 20 , 3.93 claim 20 , 3.84 claim 20 , 3.77 claim 20 , 3.70 claim 20 , 3.64 claim 20 , 3.55 claim 20 , 3.42 claim 20 , 3.37 claim 20 , 3.26 claim 20 , 3.20 claim 20 , 3.12 claim 20 , 3.05 claim 20 , 3.01 claim 20 , 2.97 claim 20 , 2.87 claim 20 , 2.82 claim 20 , 2.79 claim 20 , 2.76 claim 20 , 2.71 claim 20 , 2.67 claim 20 , 2.62. 2.59 claim 20 , 2.54 claim 20 , 2.47 claim 20 , 2.45 claim 20 , 2.43 claim 20 , 2.39 claim 20 , 2.34 claim 20 , and 2.32 angstroms.22. The compound of characterized by an x-ray powder diffraction pattern claim 20 , collected using copper K-alpha radiation claim 20 , corresponding to d-spacings of 12.81 claim 20 , 9.24 claim 20 , 8.97 claim 20 , 6.40 claim 20 , 5.83 claim 20 , 5.71 claim 20 , 5.09 claim 20 , 4.63 claim 20 , 4.58 claim 20 , 4.52 claim 20 , 4.38 claim 20 , 3.93 claim 20 , 3.84 claim 20 , 3.77 claim 20 , 3.70 claim 20 , 3.64 claim 20 , 3.55 claim 20 , 3.42 claim 20 , 3.37 claim 20 , 3.20 claim 20 , and 3.12angstroms.23. The compound of characterized by an x-ray powder diffraction pattern claim ...

PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF

The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure. 2. Compound A in its amorphous form.3. The pseudopolymorph according to claim 1 , wherein the pseudopolymorph is a hydrate alcohol solvate claim 1 , glycol solvate or ketone solvate.4. The pseudopolymorph according to claim 1 , wherein the pseudopolymorph is a hydrate claim 1 , C-Calcohol solvate claim 1 , C-Cglycol solvate or C-Cketone solvate.5. The pseudopolymorph according to claim 1 , wherein the pseudopolymorph is a mixed solvate.6. The pseudopolymorph according to claim 1 , which is pharmaceutically acceptable.7. The pseudopolymorph according to claim 1 , wherein the pseudopolymorph is selected from Form A (methanolate) claim 1 , Form B (ethanolate) claim 1 , Form C (1-propanolate) claim 1 , Form D (2-propanolate) claim 1 , Form E (acetonate) claim 1 , Form F (1-butanolate) claim 1 , Form G (ethylene glycolate) claim 1 , Form H (propylene glycolate) claim 1 , Form I (methyl isobutyl ketone/propylene glycol mixed solvate) claim 1 , Form J (hydrate) and Form K (1 claim 1 ,5-naphthalene disulfonic acid salt methanol solvate).8. The pseudopolymorph of claim 1 , which is crystalline.9. The pseudopolymoroph of claim 1 , which is selected from:{'sub': 'α', 'a methanol solvate, having an X-ray powder diffraction pattern comprising diffraction peaks at 2-theta values, when measured using Cu Kradiation, of about 6.19±0.2, 10.10±0.2, 15.76±0.2, 17.27±0.2 and 21.24±0.2;'}{'sub': 'α', 'an ethanol solvate, having an X-ray powder diffraction pattern comprising diffraction peaks at 2-theta values, when measured using Cu Kradiation, of about 6.13±0.2, 10.05±0.2, 13.30±0.2, 15.66±0.2 and 17.53±0.2;'}{'sub': 'α', 'a 1-propanol solvate, having an X-ray powder ...

Automated smart storage of products

Automated, environmentally monitored and controlled storage units and systems for storing, monitoring, and maintaining a supply of products, particularly temperature sensitive pharmaceutical and/or other high-value products, be they temperature sensitive or not. Such automated storage units contain an array of independently addressable holding locations for containers with product in one or more environmentally monitored (e.g., for temperature, humidity, etc.) and controlled zones fitted with appropriate environmental sensors. In preferred embodiments, the automated storage units also include a reader to track product information and status. Product loading, retrieval, and movement within such automated storage units is performed by a computer-controlled robot. A user interface device, preferably in communication with an application service provider to provide remotely managed inventory management and other services, provides users with inventory- and product-specific information.

Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof

Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof

The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure:.

Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv

Provided herein are compounds, compositions and methods for the treatment of Flavivirida e infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are solid forms of Compound I: (Compound I)

Crystal forms of a hcv protease inhibitor

The present invention relates to different forms of a HCV inhibitory compound.

Crystal forms of a HCV protease inhibitor

The present invention relates to different forms of a HCV inhibitory compound.

System and method for refilling inkjet cartridges

Embodiments provide an inkjet cartridge refilling system. The system may include a drill station configured to drill at least one refilling hole in an inkjet printer cartridge. The system may include an evacuation station configured to remove excess ink from the inkjet printer cartridge. In some embodiments, the excess ink is removed via a vacuum source. The system may also include a filling station configured to provide any of a plurality of inks into the cartridge. Some embodiments provide the ink to the inkjet cartridge via a hole drilled in the cartridge. Other embodiments provide the ink via inkjet nozzles of the inkjet printer cartridge. The system may also include a test station configured to test the refilled cartridge to determine whether it is functioning properly after being filled with ink.

Crystal forms of a hcv protease inhibitor.

La presente invención se refiere a diversas formas de un compuesto inhibidor de HCV.

Process for making n-sulfonated-amino acid derivatives

This invention relates to a process for preparing optically active .alpha. -amino acid substrates which are used to make potent lethal factor (LF) inhibitors for the treatment of anthrax. This invention further relates to a process for synthesis of potent LF-inhibitors for the treatment of anthrax. Specifically, the invention concerns a novel, high-yielding and highly enantioselective asymmetric hydrogenation reaction of a tetrasubstituted ene-sulfonamide acid or ester.

Inkjet refilling station

Embodiments provide an inkjet cartridge refilling system. The system may include a drill station configured to drill at least one refilling hole in an inkjet printer cartridge. The system may include an evacuation station configured to remove excess ink from the inkjet printer cartridge. In some embodiments, the excess ink is removed via a vacuum source. The system may also include a filling station configured to provide any of a plurality of inks into the cartridge. Some embodiments provide the ink to the inkjet cartridge via a hole drilled in the cartridge. Other embodiments provide the ink via inkjet nozzles of the inkjet printer cartridge. The system may also include a test station configured to test the refilled cartridge to determine whether it is functioning properly after being filled with ink.

Process for making n-sulfonated-amino acid derivatives

Formation of tetra-substituted enamides and stereoselective reduction thereof

Process for refilling inkjet cartridges

Embodiments provide a method of refilling an inkjet printer cartridge. The method includes providing an inkjet printer cartridge and lowering the pressure surrounding the cartridge below atmospheric level. A first volume of ink is directed into the cartridge at the reduced pressure. The method further includes at least partially raising the pressure surrounding the cartridge and subsequently at least partially lowering the pressure surrounding the cartridge. A second volume of ink is then directed into the cartridge at the second reduced pressure.

System and method for updating and sharing private library profile data to facilitate delivery of electronic content to libraries

A service registry that supports updating and sharing of profile data with partners. The registry allows organizations such as libraries and consortia to manage and share data that define their organizations (e.g., institution type, location, main and branch institutions, URLs for electronic services, circulation statistics, and population served). Organizations share a RSS-enabled obfuscated link with their partners that enables the partners to access a page with the latest institutional profile, and to be notified when it is updated. The obfuscation of the RSS feed provides a notification while keeping the data private. Every time a user creates an institutional profile, an equivalent RSS-enabled page is generated that can be reached through a RSS feed that has an obfuscated link name. The user shares this link with the institution's partners and others that have a need to know the information and to access details about the institution and its services.

Formation of tetra-substituted enamides and stereoselective reduction thereof

The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular, an anhydrous crystal form, Form B, and crystalline solvates falling into three patterns, Type 1, Type 2, and Type 3, and crystalline intermediate compounds produced in the process. Still further, the present invention relates to the stereoselective reduction of the tetrasubstituted enamide (II) to the corresponding amide (I).

Process for making n-sulfonated-amino acid derivatives

compound, compound pharmaceutical composition, use of a compound, method for making a compound, and preparation of a medicament

Recoiling-action wildlife feeder

A feeding apparatus for wildlife, particularly squirrels, is shown. One embodiment of the feeding apparatus includes a generally vertical, suspended flexible assembly of materials for holding a self-contained food unit. One embodiment of the feeding apparatus further includes a resilient biasing device mountable within the length of the apparatus. One end of one embodiment of the feeding apparatus includes an adjustable device for suspending the apparatus. The opposite end of one embodiment includes a device for securing the self-contained food unit. When an animal leaps up and grasps the food unit, the resilient biasing device lengthens and contracts, causing the animal to rise and fall while swinging to and fro spinning around on the apparatus. To the amusement of an observer, the animal is in effect, “bungee jumping.”

Automated smart storage of products

Automated, environmentally monitored and controlled storage units and systems for storing, monitoring, and maintaining a supply of products, particularly temperature sensitive pharmaceutical and/or other high-value products, be they temperature sensitive or not. Such automated storage units contain an array of independently addressable holding locations for containers with product in one or more environmentally monitored (e.g., for temperature, humidity, etc.) and controlled zones fitted with appropriate environmental sensors. In preferred embodiments, the automated storage units also include a reader to track product information and status. Product loading, retrieval, and movement within such automated storage units is performed by a computer-controlled robot. A user interface device, preferably in communication with an application service provider to provide remotely managed inventory management and other services, provides users with inventory- and product-specific information.

Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates

The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.

Crystal forms of a m1 receptor positive allosteric modulator

The invention is directed to novel anhydrous crystalline butenedioate salt form 1 of Compound I, which is a modulator of muscarinic M1 receptors. The novel crystalline forms of compound I are useful in the treatment or prevention of Alzheimer's disease and other disorders and diseases in which muscarinic M1 receptors are involved. The invention is further directed to pharmaceutical compositions comprising the novel crystalline forms of Compound I.

System und verfahren zum nachfüllen von tintenstrahlpatronen

Novel synthetic pathway to belzutifan and crystalline phases of synthetic intermediates

The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.

Process for preparing 3-chloromethyl-1,2,4-triazolin-5-one

Automated smart storage of products

Automated, environmentally monitored and controlled storage units and systems for storing, monitoring, and maintaining a supply of products, particularly temperature sensitive pharmaceutical and/or other high-value products, be they temperature sensitive or not. Such automated storage units contain an array of independently addressable holding locations for containers with product in one or more environmentally monitored (e.g., for temperature, humidity, etc.) and controlled zones fitted with appropriate environmental sensors. In preferred embodiments, the automated storage units also include a reader to track product information and status. Product loading, retrieval, and movement within such automated storage units is performed by a computer-controlled robot. A user interface device, preferably in communication with an application service provider to provide remotely managed inventory management and other services, provides users with inventory- and product-specific information.

Inkjet refilling adapter

Embodiments provide an inkjet cartridge refilling system. The system may include a drill station configured to drill at least one refilling hole in an inkjet printer cartridge. The system may include an evacuation station configured to remove excess ink from the inkjet printer cartridge. In some embodiments, the excess ink is removed via a vacuum source. The system may also include a filling station configured to provide any of a plurality of inks into the cartridge. Some embodiments provide the ink to the inkjet cartridge via a hole drilled in the cartridge. Other embodiments provide the ink via inkjet nozzles of the inkjet printer cartridge. The system may also include a test station configured to test the refilled cartridge to determine whether it is functioning properly after being filled with ink.